Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Jaguar Gene Therapy LLC has 1 pending office action in Biotechnology & Pharmaceuticals. The matter is assigned to 1 distinct examiner and 1 distinct art unit, resulting in one current prosecution setting.
YU, DELPHINUS DOU YI is the busiest examiner, with 1 pending matter. The defined assignment lets counsel focus on the examiner’s treatment of the gene therapy claims and supporting disclosure. A targeted response should address the pending issues while protecting the technical scope that distinguishes the application within biotechnology and pharmaceuticals.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| YU, DELPHINUS DOU YI | 1 | 33.3% | +0.0% |
| Art Unit | Apps |
|---|---|
| 1636 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18687808 | ADENO-ASSOCIATED VECTORS AND VIRIONS TO TREAT GALACTOSEMIA AND METHODS OF USE AND MANUFACTURE | YU, DELPHINUS DOU YI | 1636 | §102§103§112DPOther | Non-Final OA | — | Pending | Feb 28, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialJaguar Gene Therapy LLC has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Delphinus Dou Yi Yu has the most, with 1 of Jaguar Gene Therapy LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
